172 related articles for article (PubMed ID: 15934922)
1. Cripto as a target for cancer immunotherapy.
Hu XF; Xing PX
Expert Opin Ther Targets; 2005 Apr; 9(2):383-94. PubMed ID: 15934922
[TBL] [Abstract][Full Text] [Related]
2. Cripto monoclonal antibodies.
Hu XF; Xing PX
Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
[TBL] [Abstract][Full Text] [Related]
3. [Role of Cripto-1 protein in development and target therapy of breast cancer].
Lei T; Guo XJ; Fu L
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):66-8. PubMed ID: 20388407
[No Abstract] [Full Text] [Related]
4. Cripto-1: an embryonic gene that promotes tumorigenesis.
de Castro NP; Rangel MC; Nagaoka T; Salomon DS; Bianco C
Future Oncol; 2010 Jul; 6(7):1127-42. PubMed ID: 20624125
[TBL] [Abstract][Full Text] [Related]
5. Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma.
Wu Z; Li G; Wu L; Weng D; Li X; Yao K
BMC Cancer; 2009 Sep; 9():315. PubMed ID: 19732464
[TBL] [Abstract][Full Text] [Related]
6. Cripto: a novel target for antibody-based cancer immunotherapy.
Xing PX; Hu XF; Pietersz GA; Hosick HL; McKenzie IF
Cancer Res; 2004 Jun; 64(11):4018-23. PubMed ID: 15173016
[TBL] [Abstract][Full Text] [Related]
7. Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.
Zhang Y; Mi X; Song Z; Li Y; YingShi ; Niu J
Biomed Pharmacother; 2018 Aug; 104():729-737. PubMed ID: 29807222
[TBL] [Abstract][Full Text] [Related]
8. The threonine that carries fucose, but not fucose, is required for Cripto to facilitate Nodal signaling.
Shi S; Ge C; Luo Y; Hou X; Haltiwanger RS; Stanley P
J Biol Chem; 2007 Jul; 282(28):20133-41. PubMed ID: 17504756
[TBL] [Abstract][Full Text] [Related]
9. Role of Cripto-1 in stem cell maintenance and malignant progression.
Bianco C; Rangel MC; Castro NP; Nagaoka T; Rollman K; Gonzales M; Salomon DS
Am J Pathol; 2010 Aug; 177(2):532-40. PubMed ID: 20616345
[TBL] [Abstract][Full Text] [Related]
10. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.
Kelber JA; Panopoulos AD; Shani G; Booker EC; Belmonte JC; Vale WW; Gray PC
Oncogene; 2009 Jun; 28(24):2324-36. PubMed ID: 19421146
[TBL] [Abstract][Full Text] [Related]
11. Subtractive hybridization identifies chick-cripto, a novel EGF-CFC ortholog expressed during gastrulation, neurulation and early cardiogenesis.
Colas JF; Schoenwolf GC
Gene; 2000 Sep; 255(2):205-17. PubMed ID: 11024280
[TBL] [Abstract][Full Text] [Related]
12. The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis.
Foley SF; van Vlijmen HW; Boynton RE; Adkins HB; Cheung AE; Singh J; Sanicola M; Young CN; Wen D
Eur J Biochem; 2003 Sep; 270(17):3610-8. PubMed ID: 12919325
[TBL] [Abstract][Full Text] [Related]
13. Role of the cripto (EGF-CFC) family in embryogenesis and cancer.
Bianco C; Normanno N; Salomon DS; Ciardiello F
Growth Factors; 2004 Sep; 22(3):133-9. PubMed ID: 15518236
[No Abstract] [Full Text] [Related]
14. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
15. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development.
Minchiotti G; Parisi S; Liguori G; Signore M; Lania G; Adamson ED; Lago CT; Persico MG
Mech Dev; 2000 Feb; 90(2):133-42. PubMed ID: 10640699
[TBL] [Abstract][Full Text] [Related]
16. Cripto-1 ablation disrupts alveolar development in the mouse mammary gland through a progesterone receptor-mediated pathway.
Klauzinska M; McCurdy D; Rangel MC; Vaidyanath A; Castro NP; Shen MM; Gonzales M; Bertolette D; Bianco C; Callahan R; Salomon DS; Raafat A
Am J Pathol; 2015 Nov; 185(11):2907-22. PubMed ID: 26429739
[TBL] [Abstract][Full Text] [Related]
17. Cripto-1 expression in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Vaijayanthi P; Krishnakumar S
Exp Eye Res; 2007 Jun; 84(6):1060-6. PubMed ID: 17412323
[TBL] [Abstract][Full Text] [Related]
18. Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer.
Rangel MC; Karasawa H; Castro NP; Nagaoka T; Salomon DS; Bianco C
Am J Pathol; 2012 Jun; 180(6):2188-200. PubMed ID: 22542493
[TBL] [Abstract][Full Text] [Related]
19. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.
Gray PC; Shani G; Aung K; Kelber J; Vale W
Mol Cell Biol; 2006 Dec; 26(24):9268-78. PubMed ID: 17030617
[TBL] [Abstract][Full Text] [Related]
20. Germ cell nuclear factor is a repressor of CRIPTO-1 and CRIPTO-3.
Hentschke M; Kurth I; Borgmeyer U; Hübner CA
J Biol Chem; 2006 Nov; 281(44):33497-504. PubMed ID: 16954206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
